PubMed · 2019 · 15 citations · 33 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmune CheckpointsImmunotherapy For Solid TumorsAnimal Disease ModelsCell Line-derived Xenograft ModelsCheckpoint Antagonist TherapyHumanized Mouse ModelsImmune Checkpoint Inhibitor TherapyImmune Checkpoint ReceptorsRodent Tumor ModelsTumor Mutational Burden
or peripheral blood mononuclear cells, we can create a human immune system capable of mounting a response against tumor burden. These animal models are currently being used to study molecular mechanisms, test drug efficacy, and trial drug combinations. Others have found use for these humanized mouse models as surrogates to represent otherwise uncommon diseases. Limitations remain with regards to what the models are capable of, but in the short amount of time between the development of these models and heightened interest in ICBs, these mice have already shown utility for future developments in the field of immunotherapy.
33
CTLA-4 can function as a negative regulator of T cell activation
Theresa L. Walunas, Deborah J. Lenschow, Christina Y. Bakker et al. · Immunity · 1994 · 2.2K citations
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chainnull mice
Fumihiko Ishikawa, Masaki Yasukawa, Bonnie Lyons et al. · Blood · 2005 · 920 citations · Full text
Life Sciences, Immunology, Pathology +15
Kenneth D. Kochanek, Sherry L Murphy, Jiaquan Xu et al. · PubMed · 2019 · 461 citations